Lawrence Fong

MD

Genitourinary oncologist
Cancer immunotherapy program leader and lab researcher

About me

Dr. Lawrence Fong is a specialist in genitourinary cancer at UCSF Medical Center. He is particularly interested in tumor immunology – the role of the immune system in cancer – and developing immune-based treatments. He earned his undergraduate degree from Columbia University and his medical degree from Stanford University. He completed an oncology fellowship at Stanford, then joined the medical staff there in 1999. Fong came to UCSF in 2002.

  • Education

    Stanford University, 1992

  • Residencies

    University of Washington, Internal Medicine, 1994

  • Fellowship

    Stanford University, Oncology, 1997

  • Academic Title

    Professor

My goal is to improve treatment of cancer through immunotherapy.

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Prostate Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Decorative Caduceus

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced canc...

Recruiting

Decorative Caduceus

Pembrolizumab in Combination With Intratumoral SD-101 Therapy

This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in patients with newly diagnosed horm...

Recruiting

Decorative Caduceus

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Infor...

This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received ...

Recruiting

Decorative Caduceus

Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before...

This phase II trial studies how well atezolizumab works alone or in combination with enzalutamide in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies,...

Recruiting

Decorative Caduceus

Neoadjuvant Atezolizumab in Localized Bladder Cancer

This is a single arm, open label Phase II study of MPDL3280A, an anti-PD-L1 antibody administered as neoadjuvant therapy to subjects with either BCG-refractory non-muscle invasive transitional cell carcinoma (TCC) of...

Recruiting

Decorative Caduceus

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combinati...

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will s...

Recruiting

Decorative Caduceus

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Da...

This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.

Recruiting

Decorative Caduceus

Study of HPN424 in Patients With Advanced Prostate Cancer

An open-label, Phase 1, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy

Recruiting

Decorative Caduceus

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants Wit...

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination wit...

Recruiting

Share